Takeda new debts to EBITDA ratios targeted until 2023

Targeted net debt to EBITDA ratio of Takeda Pharmaceutical after Shire deal until 2023

by Matej Mikulic, last edited Feb 12, 2019
Takeda new debts to EBITDA ratios targeted until 2023 This statistic depicts the targeted net debt to EBITDA ratio of Takeda Pharmaceutical after the Shire deal, until March 2023, by deleveraging case. The ratio of debts to EBITDA before the Shire deal in standalone deleveraging cases was 1.6.
Show more

Targeted net debt to EBITDA ratio of Takeda Pharmaceutical after Shire deal until 2023

You need to log in to download this statistic
Register for free
Already a member?
Log in
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Pharmaceutical industry in Italy"
  • Industry overview
The most important statistics
  • Key players
  • International trade
  • Research and development
  • CDMO
  • Forecasts
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.